Centchroman Regress Mastalgia and Fibroadenoma: An Institutional Study
Journal Title: Journal of Medical Science And clinical Research - Year 2016, Vol 4, Issue 7
Abstract
Objectives: Centchroman (also known as Ormeloxifene) is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts selectively on the estrogen receptor. Because of its selective antiestrogen action, centchroman has been used for treatment of mastalgia and fibroadenoma. Materials And Methods: Benign breast disease patients up to 35 years of age attending surgery outpatient department from August 2012 to September 2014 and fulfilling inclusion criterion were included in the study. The patients were started on centchroman 30 mg on daily for a period of 12 weeks and were followed at weeks 4, 8, 12, and 24 to assess response to therapy. The Results were recorded as per clinical examination, ultrasonography for breast lump size and visual analog scale (VAS) for pain. Results: A total of 130 patients were included in the study, 88 (67.70%) of whom had mastalgia with or without nodularity, and 42 (32.30%) had fibroadenoma. Noncyclical pain was in 71 patients (80.70%), and cyclical pain was recorded in only 17 (19.30%) patients. A VAS score of 10 was recorded by 62 (70.50%) patients (severe pain), and the remaining 26 patients (29.50%) had VAS score from 7 to 10. Fibroadenoma size ranged from 1.5 to 5 cm, single or multiple in one or both breast. There was a good response in the mastalgia group, with a decrease in the VAS scoring from 10 to 3 in 69 (78.40%) of the patients in the first week. Almost all of the patients were painless at the end of first month, with complete disappearance of the nodularity. In the fibroadenoma group there was a mixed response, with complete disappearance in 21 (35%), partial regression (decrease in volume of fibroadenoma) in 29 (48.30%) and no response at all in the remaining 10 (16.70%) a period of 6 months. There were few side effects with scanty menses or amenorrhea as the only side effect. Conclusions: Centchroman is a safe drug for the treatment of mastalgia and fibroadenoma. It has shown good results in mastalgia and fibroadenoma, is an effective, safe and inexpensive
Authors and Affiliations
Bhupender Sharma
Keywords
Related Articles
- EP ID EP213807
- DOI -
- Views 56
- Downloads 0
To Study the Association of Free Insulin Levels, Obesity Markers & Lipid Profile Parameters in Newly Diagnosed Patients of Type 2 Diabetes Mellitus in Tertiary Care Centre of Kumaon Region
Diabetes Mellitus is the commonest metabolic abnormality in the world. Type 2 diabetes the commonest form of diabetes constitutes nearly 90% of diabetic population in any country. Type 2 diabetes mellitus is characterize...
Myocardial Infarction in Young Indian Patients Risk Factors Analysis
Background: Coronary artery disease (CAD) mostly occurs in persons older than 45 years of age. In India, CAD manifests almost a decade earlier than in Western countries. This study was done to study the risk factors and...
Analysis of Biomarkers (Homocystine/CRP) as Risk Factors for Age-Related Macular Degeneration: A Case Control Study
Introduction: Age Related Macular Degeneration (AMD) is a progressive disorder of the macular area that becomes clinically apparent usually after 50 years of age. When it progresses to advanced stages it can result in se...
Study of Pulmonary Function Tests During Pregnancy At Physiological Variable Conditions
Pregnancy is one of the most critical states of physiological adaptation during which many physiological adjustments occur to meet the requirement of foetus as well as mother. Such studies are the key to understand and h...
Late Complication of Renal Transplantation Presenting As LymphoceleCase Report and Literature Review
A 26-year-old man who had undergone renal transplantation one year ago came for regular check –up. On examination his BP was 170/100bpm and pedal oedema was noted in bilateral lower limbs. Further investigation revealed...